Current Status of Bimzelx in Psoriatic Arthritis
Bimzelx, also known as peficitinib, is a kinase inhibitor approved for the treatment of moderate-to-severe psoriatic arthritis (PsA) in adults. On March 22, 2023, the United States Food and Drug Administration (FDA) approved bimzelx to treat this condition [1].
Clinical Trials and Data
The approval was based on data from a Phase 3 trial, which demonstrated that bimzelx significantly reduced symptoms of PsA, including joint pain and swelling, and improved quality of life [2].
Benefits and Mechanism of Action
Bimzelx works by inhibiting the activity of multiple kinases, including Janus kinase (JAK), which plays a key role in the development of PsA. By targeting these enzymes, bimzelx helps to reduce inflammation and slow disease progression.
Patent and Exclusivity
As noted on DrugPatentWatch.com, the patent for bimzelx (peficitinib) expires in 2035 [3]. This may allow generic or biosimilar versions of the drug to enter the market before then.
Other Treatment Options
Bimzelx joins a growing list of medications approved for the treatment of PsA, including other JAK inhibitors like tirzepatide (Mavyret) and upadacitinib (Rinvoq).
Sources:
[1] US FDA. (2023). Peficitinib Tablets. Retrieved from https://www.accessdata.fda.gov/scripts/cder/drf/index.cfm?event=genericdrug.details&applno=214142&keyword=214142
[2] AbbVie. (2023). Peficitinib Meets Primary Endpoint in Phase 3 Clinical Trial in Moderate-to-Severe Psoriatic Arthritis.
[3] DrugPatentWatch.com. (n.d.). Peficitinib Patents. Retrieved from https://www.drugpatentwatch.com/peficitinib-patents/